Interventional × Bile Duct Neoplasms × pembrolizumab × Clear all
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 5 FDA
NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Carisma Therapeutics Inc

Phase 1 Active not recruiting
48 enrolled
NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled